Huperzine A and cognition

What 3 graded rows on huperzine a agree on for cognition, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Huperzine A page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Huperzine A page, with its PubMed record.

Your question

Cognition3

Supplement

Huperzine A Choose another

Huperzine A and cognition

3 rows · 2,487 people

Mostly an improvement: 2 of 3 rows, and most of the people. 1 found no difference.

No difference

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside.

Grade C× 2
No effect× 1

Rows: 3
Trials: 27
People: 2,487; Pooled reviews may count some twice

Where they differ

From the rows

Trial sizeStudy designHow long

The best-graded row, grade C, is a meta-analysis of 1,823 people (2013) and found an improvement. 1 row is graded No effect, our grade for adequately powered trials that found no effect.

The 2 rows that found an improvement were larger: a median of 1,139 people, against 210 people for the row that found no difference.

The 2 rows that found an improvement are pooled reviews of several trials; the row that found no difference is a single study.

The row that found no difference ran longer (4 months) than the 2 rows that found an improvement (6 to 8 weeks).

The rows

2 improved · 1 no difference

Grade CCognition and daily function in Alzheimer disease · Improved
Meta-analysis, 20 studies · n 1,823 · 2013 · People with Alzheimer disease in 20 RCTs (mostly in China)
Varied across trials · 8–16 weeks for most outcomes
MMSE and other scores improved versus placebo, but most trials had high risk of bias.
Row on the Huperzine A page · PubMed 24086396 (opens PubMed)
Grade CGeneral cognitive function in Alzheimer disease · Improved
Systematic review, 6 studies · n 454 · 2008 · People with Alzheimer disease in 6 trials
Varied across trials · 6–12 weeks for ADAS-Cog
MMSE improved by 2.81 points versus placebo, but only one trial was of adequate quality and size, so evidence was judged inadequate for a recommendation.
Row on the Huperzine A page · PubMed 18425924 (opens PubMed)
No effectADAS-Cog in mild to moderate Alzheimer disease · No difference
RCT · n 210 · 2011 · Adults with mild to moderate Alzheimer disease (US multicentre)
200 mcg or 400 mcg twice daily · 16 weeks
200 mcg twice daily did not change ADAS-Cog versus placebo (primary outcome); 400 mcg twice daily showed a secondary-analysis signal.
Row on the Huperzine A page · PubMed 21502597 (opens PubMed)

NextWhere to buyProducts that contain it. Check the amount per serving against the doses in these rows.